A cup of hot tea to welcome you!


Welcome to Wikiafripedia, the free encyclopedia that you can monetize your contributions. Aimed at WAP ZERO to the sum of all knowledge.
WAP is made by people like you, sign up and contribute.

A cup of hot tea to welcome you!

Welcome to Wikiafripedia, the free encyclopedia that you can monetize your contributions. Aimed at WAP ZERO to the sum of all knowledge.


WAP is made by people like you, sign up and contribute.

CanSino Biologics

From Wikiafripedia, the free encyclopedia that you can monetize your contributions or browse at zero-rating.
Jump to navigation Jump to search

CanSino Biologics Inc.
CanSinoBIO
Native name
康希诺生物
Founded2009; 12 years ago (2009) in Tianjin, China
Founders
  • Yu Xuefeng
  • Zhu Tao
  • Qiu Dongxu
  • Helen Mao Huihua
Headquarters,
China
Website

CanSino Biologics (Chinese: 康希诺生物; pinyin: Kāngxīnuò Shēngwù), often abbreviated as CanSinoBIO, is a Chinese vaccine company.[1]

History[edit source | edit]

CanSino Biologics was founded in 2009 in Tianjin, China by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.[1]

In July 2018, it filed an application to list on the Hong Kong Stock Exchange.[1] It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017.[2]

Vaccines[edit source | edit]

The company has a portfolio of vaccines under research including Ad5-EBOV to prevent Ebola and Ad5-nCoV for COVID-19. Both are developed jointly with the Institute of Biotechnology of the Academy of Military Medical Sciences of the People's Liberation Army.[1][3]

The company has also collaborated with the National Research Council of Canada on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.[4]

In March 2020, CanSino made a deal to collaborate with the NRC on development of the COVID-19 vaccine candidate Ad5-nCoV, to help end the COVID-19 pandemic, with plans to conduct a clinical trial in Canada.[5] Ad5-nCoV was the first COVID-19 vaccine candidate in the world to begin Phase II human trials.[4]

In early July, CanSino Biologics began talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, with the company planning to recruit 40,000 participants for the test. Co-Founder Qiu Dongxu said its Phase II trial involving 508 people has yielded “much better” results than the Phase I about the safety and ability to trigger immune response but did not disclose specific evidence. [6]

Investors[edit source | edit]

As of 2018, CanSino Biologics investors included Lilly Asia Ventures, Qiming Venture Partners and SDIC Fund Management.[1]

See also[edit source | edit]

References[edit source | edit]

  1. 1.0 1.1 1.2 1.3 1.4 Ng, Eric (25 July 2018). "Chinese vaccine maker CanSino faces tough IPO sell in wake of Changsheng Bio-technology scandal". South China Morning Post. Retrieved 18 April 2020.
  2. Low, Zoe (29 March 2019). "Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China's domestic market". South China Morning Post. Retrieved 18 April 2020.
  3. Pinghui, Zhuang (10 April 2020). "Volunteers needed for second phase of China coronavirus vaccine trial". South China Morning Post. Beijing. Retrieved 18 April 2020.
  4. 4.0 4.1 Canada, National Research Council. "The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19". www.newswire.ca. Retrieved 19 May 2020.
  5. DeArment, Alaric (13 May 2020). "CanSino Biologics may start clinical development of Covid-19 vaccine in Canada". MedCity News. Retrieved 19 May 2020.
  6. https://www.reuters.com/article/us-health-coronavirus-china-vaccine/chinas-cansino-in-talks-for-covid-vaccine-phase-iii-trial-overseas-idUSKCN24C0HS

External links[edit source | edit]